

Public Declaration of Interests and Confidentiality Undertaking of Swissmedic Medicines Expert Committee Members

This document is aligned to the 'Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA) Scientific Committee members and experts' of the EMA.

SECTION 1: PERSONAL DETAILS

First Name	Andreas
Last Name	Cerny
Organisation / Company	Clinica Luganese, Moncucco
Country of Organisation / Company	Switzerland
Committee	Human Medicines Expert Committee (HMEC)

I do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below.

Please specify the interests that you currently have (at the time of completion of the form) or have had within the past 5 years.

SECTION 2: PUBLIC DECLARATION OF INTERESTS**2.1 Employment** No Yes

Please indicate if you are employed / have been employed, either full or part time, either as paid or unpaid employee in pharmaceutical company.

Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

2.2 Consultancy

No Yes

Choose "Yes" if there is any activity in which you provide or have provided advice or services regardless as to whether or not you received a fee for this activity. Please indicate all of them below.

Provision of advice or services to a pharmaceutical company (in a particular field such as the development of a product) regardless of contractual arrangements or any form of remuneration. (Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product)

Involvement in Data Safety Monitoring Committee should be included in this section.

Note: Conference / Seminar attendance is not considered as consultancy but should be indicated under Financial Interests, if subject to a fee / honoraria.

Period	Company	Product	Therapeutic Indication <i>General Role / Area of Activity</i>	Funding
07/2025 - TODAY	BASILEA - DRUG SAFETY MONITORING BOARD	Fosmanogepix	Indication: Fungal Infections	

2.3 Strategic Advisory Role

No Yes

Choose "Yes" if you are participating or have participated in a (Scientific) Advisory Board/Steering Committee of a pharmaceutical company (e.g. board membership / directorship), with a right to vote on / influence the outcome of that body.

Participation (with a right to vote on/influence the outputs) in a (Scientific) Advisory Board/Steering Committee with the role of providing advice/expressing opinions on the (future) strategy, direction or development activities of a pharmaceutical company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration. Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

Note: Involvement in Data Safety Monitoring Committees is not included in this category. Such involvement should be recorded under section 2.2 Consultancy. Involvement in clinical research should be listed under section 2.6 Principal Investigator or 2.7 Investigator as appropriate.

2.4 Current Financial Interests

No Yes

Choose "Yes" if you have any financial interests currently held in a pharmaceutical company.

Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pension. Compensation, fees, honoraria, salaries currently being paid directly to you by a pharmaceutical company, other than payment for expenses incurred with research work or re-imbursment of reasonable expenses incurred in relation to conference/seminar attendance (i.e. accommodation and travel costs).

Current is interpreted at time of completion of this form.

2.5 Patent

No Yes

Choose "Yes" if any patent for a medicinal / competitor product is currently owned by either yourself or your institution and you are a beneficiary.

Current is interpreted at time of completion of this form.

2.6 Principal Investigator

No Yes

Choose "Yes" if there are trials for which you are acting or have acted as Principal Investigator

Principal Investigator with the responsibility for the coordination of investigators at different centres participating in a multicentre trial or the leading investigator of a monocentre trial, or the coordinating (principal) investigator signing the clinical study report. This definition does not include a national coordinating investigator in a multinational trial.

Period	Company	Product	Therapeutic Indication <i>General Role / Area of Activity</i>	Funding
12/2013	BASILEA - DRUG SAFETY MONITORING BOARD	BAL 30072	Bacterial Infections	no
07/2017 - 12/2019	BASILEA - DRUG SAFETY MONITORING BOARD	CEFTOBIPROLE	Bacterial Infections	no
10/2020 - 09/2022	Fondazione Epatocentro Ticino	Methylene Blue	COVID-19	yes
02/2025 - TODAY	Fondazione Epatocentro Ticino	Methylene Blue	Chronic HBV	yes
04/2025 - TODAY	Boehringer Ingelheim	Survodutide	Cirrhotic NASH	yes
04/2025 - TODAY	Boehringer Ingelheim	Survodutide	Fibrotic NASH	yes

2.7 Investigator

No Yes

Choose "Yes" if there are trials for which you are acting or have acted as Investigator.

Investigator involved in a clinical trial at a specific trial site who can be the responsible lead investigator of the trial at that specific site or a member of the clinical trial team who performs critical trial related procedures and makes important trial related decisions.

Period	Company	Product	Therapeutic Indication General Role / Area of Activity	Funding
01/2013 - 09/2015	ABBVIE	ABT538, ABT450, ABT333, ABT267	Hepatitis C	yes
11/2015 - 04/2017	ABBVIE	ABT493, ABT530	Hepatitis C	yes
03/2017 - 04/2018	AbbVie	Viekirax / Exviera	Hepatitis C	yes
06/2017 - 04/2019	Gilead Sciences, Inc.	Selonsertib	NASH Non-Alcoholic Steatohepatitis	yes
07/2017 - 10/2023	Intercept Pharmaceuticals, Inc.	Obeticholic Acid	NASH Non-Alcoholic Steatohepatitis	yes
10/2017 - 04/2019	Novartis	LMB763	NASH Non-Alcoholic Steatopatitis	yes
02/2018 - 01/2020	AbbVie AG	Maviret: Glecaprevier plus Pibrentasvir	Hepatitis C	yes
06/2017 - 12/2020	Inventiva SAS	IVA 337	NASH Non-Alcoholic Steatohepatitis	yes
12/2017 - 09/2023	Novartis	Deferasirox	Hereditary hemochromatosis	yes
02/2018 - 06/2022	Novartis	VAY736/ianalumab	AIH Autoimmune Hepatitis	yes

02/2018 - 12/2020	The Kirby Institute-Australia	Sofosbuvir/velpatasvir	Hepatitis C	yes
02/2018 - 08/2020	University Hospital of Lausanne (CHUV)	Fluzone-HD; Fluad;VaxigripTetra	Influenza	yes
02/2019 - 10/2020	Novartis	combination treatment of tropifexor (LJN452) and cenicriviroc (CVC)	NASH / liver fibrosis	yes
03/2019 - 09/2024	Dr. Falk Pharma GmbH	norursodeoxycholic acid	PSC Primary Sclerrosing Cholangitis	yes
10/2021 - 10/2023	BMS Bristol-Myers Squibb	IM025017	Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)	yes
03/2021 - 07/2023	Genfit	Elafibranor	PBC Primary Biliary Cholangitis	yes
01/2021 - 09/2022	Gilead Sciences, Inc.	Cilofexor	Primary Sclerosing Cholangitis	yes
08/2023 - 03/2025	MSD Merck Sharp & Dohme	Efinopegdutide	NASH Non-Alcoholic Steatohepatitis	yes
02/2023 - 03/2024	GSL Glaxo SmithKline	Linerixibat	Primary Biliary Cholangitis (PBC) and Pruritus	yes
01/2023 - 04/2025	Dr. Falk Pharma GmbH	Norucholic Acid	Primary Biliary Cholangitis PBC)and inadequate response to Ursodeoxycholic acid	yes
10/2022 - 03/2024	Calliditas Therapeutics Suisse SA	Setanaxib	Primary Biliary Cholangitis (PBC)and elevated liver stiffness	yes

01/2021 - 09/2023	Madrigal Pharmaceuticals Inc.	MGL-3196 (Resmetirom)	NASH Non-Alcoholic Steatohepatitis	yes
----------------------	-------------------------------	-----------------------	---------------------------------------	-----

12/2024 - TODAY	Akero Therapeutics	Efruxifermin	NASH	yes
--------------------	--------------------	--------------	------	-----

2.8 Grant / Funding to organisation/institution

No Yes

Choose "Yes" if any grants or other funding is currently received by your institutional unit from a pharmaceutical company and you receive no personal gain; or where your Organisation (e.g. Patient Organisation) receives a grant or other funding from a pharmaceutical company and you (irrespective if you are employed by the Organisation or are a volunteer) receive no personal gain.

Refers to a grant or other funding from a pharmaceutical company, currently being received (as far as the individual is aware) by an institution (please indicate funding to the smallest institutional unit) or an organisation (e.g. patient organisation), irrespective of whether or not the individual is employed or is a volunteer, and the individual receives no personal gain.

2.9 Any other interests or facts

No Yes

Choose "Yes" if further to the interest declared above you have any other interests or facts that should be made known to Swissmedic, the Swiss Agency of Therapeutic Products and the public.

By choosing "No" you declare on your honour that you do not have any other interests or facts to declare accordingly.